Company / PP&E (Net)
Wave Life Sciences Ltd. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$7.4M
FY2025
5-year range
$7.4M / $22.3M
FY2021-FY2025
Trend
-26.9%
vs FY2024
Sector context
#103 of 193
Health Care
What the data says
At $7M, Wave Life Sciences Ltd.'s pp&e (net) ranks #103 of 193 in the Health Care sector. PP&E (Net) has declined for 7 consecutive years, from $40M in FY2018 to $7M in FY2025.
Based on SEC 10-K filings.
$7M in FY2025 with a 5-year CAGR of -24.0%.
Declined from $13M to $7M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -24.6%
- 5-Year CAGR
- -24.0%
- 10-Year CAGR
- -
Sector benchmark
#103 of 193 in Health CareTop 53% of 193This company $7.4M Sector average $777.6M
▼
-99.0% below sector average
Key checks
Key Insights
- Wave Life Sciences Ltd.'s pp&e (net) has declined for 7 consecutive years.
- 5-year CAGR of -24.0%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 26.9% year-over-year.
- Ranks #103 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.4M | -26.9% |
| FY2024 | $10.1M | -22.6% |
| FY2023 | $13.1M | -24.3% |
| FY2022 | $17.3M | -22.4% |
| FY2021 | $22.3M | -23.7% |
| FY2020 | $29.2M | -19.7% |
| FY2019 | $36.4M | -8.9% |
| FY2018 | $39.9M | +46.1% |
| FY2017 | $27.3M | +217.6% |
| FY2016 | $8.6M | +208.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026